Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treatment of Advanced Colorectal Cancer: A Si

Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treatment of Advanced Colorectal Cancer: A Single-arm, Phase II Clinical Study is a phase 2, interventional study registered as NCT07047560 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 46 participants, started 2024-09-01 and due to reach its primary completion in 2026-08-01. Interventions recorded: fractionated liposomal irinotecan (II)-based combination chemotherapy (FOLFIRInali-3) plus bevacizumab (Bev). Conditions listed: Colorectal Cancer (CRC). Primary outcome: Objective Response Rate,ORR. Colorectal eligibility wording from the registry: "Patients with pathologically confirmed advanced colorectal carcinoma (all other histological types excluded);". Sites: China. No results are recorded here; the registry entry is the source.